Results of ALTA-1 trial: Patients given brigatinib saw a statistically significant 51 percent reduction in the risk of progression or death compared with those given crizotinib.
Data presented today from the randomized COAPT trial, which have the potential to significantly change current clinical practice, found that patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally tolerated medical therapy demonstrated reduced rates of hospitalizations and death, as well as improved quality-of-life and functional capacity after being treated with the transcatheter MitraClip device.
A multicenter clinical trial has found that a minimally invasive procedure called transcatheter mitral valve repair significantly reduced hospitalizations and mortality for heart failure patients with moderate-to-severe or severe functional mitral regurgitation.
Taking a low-dose aspirin daily does not prolong healthy living in older adults, according to findings from the ASPirin in Reducing Events in the Elderly (ASPREE) trial published online Sept. 16 in three papers in The New England Journal of Medicine.
A DNA-based analysis of blood cells soon after a stem cell transplant can predict likelihood of disease recurrence in patients with myelodysplastic syndrome (MDS), a group of cancerous disorders characterized by dysfunctional blood cells, according to new research at Washington University School of Medicine in St. Louis. Such a practice could help doctors identify patients at high risk of disease recurrence early after a transplant and help guide treatment decisions.
To protect the public from harmful products, legal action can be used against industries, one example of which—a settlement with the tobacco industry—offers useful lessons for confronting several of today’s public health epidemics.
Ronald G. Victor, MD, a prominent hypertension expert and the first investigator to scientifically prove that thousands of lives could be saved annually if barbers were enlisted to help fight the epidemic of high blood pressure in the African-American community, died Monday, Sept. 10.
A single dose of a new influenza drug can significantly shorten the duration of the illness in teens and adults, according to a study published in the prestigious New England Journal of Medicine.
A promising drug slowed brain shrinkage in progressive multiple sclerosis (MS) by nearly half, according to new research led by Cleveland Clinic. Very limited therapies are currently available for this disabling form of the disease. The definitive results of the phase 2 trial – published in the New England Journal of Medicine – showed that the drug ibudilast decreased progression of brain atrophy in progressive MS patients by 48 percent versus placebo.
A study led by Columbia University cardiologist Mathew Maurer showed that tafamidis reduces deaths from a type of heart failure called transthyretin amyloid cardiomyopathy. The drug could be one of the first effective treatments for the disease.
Combination immunotherapy shrank melanoma that has spread to the brain in more than half of the patients in a clinical trial reported in the New England Journal of Medicine led by an investigator at The University of Texas MD Anderson Cancer Center.
Community outreach and educational support for navigating health insurance options available in the Affordable Care Act (ACA) marketplace are crucial for helping people choose the best plan based on their individual needs, according to researchers, health policy experts and community partners across Missouri – one of 19 states that hasn’t expanded Medicaid eligibility. Such efforts at the state level likely contributed to a higher enrollment in ACA plans among Missourians in 2018 than in 2017.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Inducing labor in healthy first-time mothers in the 39th week of pregnancy results in lower rates of cesarean sections compared with waiting for labor to begin naturally at full term, according to a multicenter study funded by the National Institutes of Health (NIH). Additionally, infants born to women induced at 39 weeks did not experience more stillbirths, newborn deaths or other major health complications.
Before Medicaid work requirements get into full gear, a team of Medicaid researchers is offering specific recommendations to help states ensure that they don’t harm the health of people enrolled in Medicaid. They recommend focusing on adults under 50 in expansion plans, clearly guiding physicians on certifications, offering services to support working and job-seeking enrollees, and spacing out reporting periods to fit modern work patterns.
Inducing labor in healthy women at 39 weeks into their pregnancy reduces the need for cesarean section and is at least as safe for mother and baby as waiting for spontaneous labor. Choosing to induce could also reduce the risk that mothers will develop preeclampsia and that newborns will need respiratory support after delivery, according to a study publishing in the New England Journal of Medicine on August 8.
UCSF Benioff Children’s Hospital Oakland clinical researchers, in conjunction with other sickle cell centers and scientists at Emmaus Life Sciences, Inc., have demonstrated that therapy with L-Glutamine reduced the frequency of pain episodes in both pediatric and adult patients with sickle cell disease (SCD). The results of the 48-week, phase 3 clinical trial are published in the July 19, 2018, issue of New England Journal of Medicine (NEJM).
Two units of plasma given in a medical helicopter on the way to the hospital could increase the odds of traumatically injured patients with severe bleeding surviving by 10 percent, according to the results of a national clinical trial.
A payment system that provides financial incentives for hospitals that reduce health-care costs for Medicare patients did not lower costs as intended, according to a new study led by Washington University School of Medicine in St. Louis.
A monthly roundup of research briefs showcasing recent scientific advances led by Beth Israel Deaconess Medical Center faculty.
A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial.
In an article published today in the New England Journal of Medicine, University of Pennsylvania researchers call for modernizing the way Medicare pays for training nurses, and highlight a successful new model of cost-effectively training more advanced practice nurses to practice community-based primary care.
A combination of the drugs mifepristone and misoprostol can help bring closure to some women and their families suffering from miscarriage, and reduces the need for surgical intervention to complete the painful miscarriage process. Results of a new clinical trial led by researchers at the Perelman School of Medicine at the University of Pennsylvania, show that while the standard drug regimen using misoprostol on its own frequently fails to complete the miscarriage, a combination of misoprostol and the drug mifepristone works much more reliably.
Clinical trials show that an immune checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of a common skin cancer, an international team led by a researcher at The University of Texas MD Anderson Cancer Center reports in the New England Journal of Medicine.
A 21-gene test could enable most patients with the most common type of early breast cancer to safely forgo chemotherapy, according to a landmark study published in the New England Journal of Medicine. Loyola Medicine oncologist Kathy Albain, MD, is among the main co-authors.
Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia (AML) with relapsed or refractory disease.
Free smoking cessation aids, such as nicotine patches and chewing gum, are a staple of many corporate wellness programs aimed at encouraging employees to kick the habit. But, new research shows that merely offering such aids for free does not help employees quit, whereas supplementing them with financial incentives is three times more effective. The study also provides the first large-scale evidence that offering e-cigarettes to known smokers is not effective at helping smokers stay smoke-free.
Writing in a new Perspective published in the New England Journal of Medicine, researchers from Penn Medicine’s Center for Health Care Innovation argue that Electronic Health Records should be restructured from mere digital remakes of their old pen and paper ancestors into platforms that allow doctors to “subscribe” to their patients’ clinical information to receive real-time updates when an action is required, similar to social media feeds and notifications.
Families of critically ill hospital patients report higher satisfaction with clinician communication and a better perception of patient-centered care when the care team uses a low-cost strategy involving intensive emotional support and frequent meetings.
Two new studies of patients with difficult-to-control asthma show that the eczema drug dupilumab alleviates asthma symptoms and improves patients’ ability to breathe better than standard therapies. Dupilumab, an injectable anti-inflammatory drug, was approved in 2017 by the Food and Drug Administration as a treatment for eczema, a chronic skin disease.
Overall antibiotic use was not curbed by giving physicians the results of biomarker tests in patients with suspected lower respiratory tract infections, according to findings from the Procalcitonin Antibiotic Consensus Trial.
The researchers examined 17 years of transplantation records and found no significant change in the recipients’ chance of survival when the organ donation came from victims of drug intoxication. The study publishes online on May 17 in the New England Journal of Medicine.
People with mild asthma are often prescribed a daily treatment regimen, but up to 80 per cent do not follow the routine, using inhalers only when they have an asthma attack. Now the researchers have found an as-needed combined-drug inhaler is a viable treatment option.
Given the complex and rapidly evolving health care system in the United States, medical schools must focus their efforts on training more physician leaders to master the diverse skills needed to navigate emerging challenges in the field, urge leaders from the Perelman School of Medicine at the University of Pennsylvania in a new Perspective piece published today in the New England Journal of Medicine.
A new analysis highlights an ironic development in the intertwined issues of immigration and health care – two areas where the current and previous administrations differ greatly. Undocumented people may now get more medical help as states gain more flexibility in health care.
A letter in the May 3, 2018, NEJM updates reports on the risks of exposure during pregnancy to a supplement, diethylstilbestrol (DES), that is linked to a rare cancer. DES-exposed patients with clear-cell adenocarcinoma had “increased mortality across their life span.”
Physician scientist Christopher Seymour talks about his experience treating sepsis patients and his new study indicating that quicker treatment improves survival odds.
In a review published today in the New England Journal of Medicine, Gregory R. Ciottone, MD, Director of the Division of Disaster Medicine in the Department of Emergency Medicine at BIDMC, advocates for an overhaul to the systems currently in place to respond to a chemical weapons strike on U.S. soil. In addition to calling for increased training and awareness, Ciottone also proposed a triage system – available online – based on recognizing the signs and symptoms of specific agents during the early phase of a chemical weapons attack.
Interim results of clinical trials by investigators at UCSF Benioff Children’s Hospital Oakland and Ann and Robert H. Lurie Children’s Hospital of Chicago reveal that a majority of the 22 patients in two Phase 1/2 studies followed for two years or longer remained free from transfusions. The results of the trials “Gene Therapy in Patients with Transfusion-Dependentβ-Thalassemia,” are published today in the New England Journal of Medicine (NEJM). The results are from two separate, two-year clinical studies using LentiGlobin® gene therapy to stop or reduce chronic blood transfusions in patients with transfusion-dependent β-thalassemia (TDT).
Washington University School of Medicine in St. Louis and Epharmix, a digital health company, have created a new automated text messaging service that may curb opioid abuse and prevent relapse. Patients receive text messages to gauge if they’re feeling OK or struggling with potential relapse. Patients also can activate a panic button to request immediate help.
The U.S. Food and Drug Administration granted approval to the combination of two immunotherapy drugs, ipilimumab and nivolumab, for the treatment of metastatic kidney cancer.
The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to chemotherapy alone, according to an international, Phase III clinical trial.
A drug given to early stage lung cancer patients before they undergo surgery showed major tumor responses in the removed tumor and an increase in anti-tumor T-cells that remained after the tumor was removed, which resulted in fewer relapse cases in the patients.
Results show supplement is no better than placebo in relieving signs and symptoms of disease.
Findings from a new randomized clinical trial, now show that contrary to a long held belief in the ophthalmic community, omega-3 supplements are no more effective than placebo at alleviating dry eye symptoms.
Omega-3 fatty acid supplements taken orally proved no better than placebo at relieving symptoms or signs of dry eye, according to the findings of a well-controlled trial funded by the National Eye Institute (NEI), part of the National Institutes of Health.
In a review article published April 5 in the New England Journal of Medicine, scientist Andrew Feinberg, M.D., calls for more integration between two fields of DNA-based research: genetics and epigenetics.
Special report details serious concerns that medical community would be able to do much, if anything, to assist people in event of major nuclear event. Prevention is best option as well as carefully conceived, long-term plan within the public education system to provide lessons on radiation biology
Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo®) and ipilimumab (Yervoy®) significantly increased overall survival versus treatment with sunitinib (Sutent®) alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) that were reported today in the New England Journal of Medicine.
Limiting first-year medical residents to 16-hour work shifts, compared to “flexing” them to allow for some longer shifts, generally makes residents more satisfied with their training and work-life balance, but their training directors more dissatisfied with curtailed educational opportunities. That’s one conclusion of a new study published online March 20 in the New England Journal of Medicine.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right